arrow
S

Satoshi Yuki

Hokkaido University Hospital
H指数:24
被引数:2,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study

奥塞罗研究:一项关于regorafenib和FTD/TPI在转移性结直肠癌中治疗顺序的前瞻性观察研究

2026-09-290
PRE
Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study

三氟尿idine/替吡拉塞与或不与贝伐珠单抗联用治疗微卫星不稳定性高/错配修复缺陷型转移性结直肠癌:一项回顾性观察性研究

2026-08-060
PRE
Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: The BEETS (JACCRO CC‑18) study

encorafenib、cetuximab ± binimetinib治疗BRAF突变型转移性结直肠癌的真实世界疗效:BEETS(JACCRO CC-18)研究

2026-02-270
OA
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)

盐酸安莫妙早期停药预测因素:胃肠道癌相关恶病质的多中心回顾性队列研究(HGCSG2201)

2026-02-190
PRE
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Scrum-monstar癌症组学生态系统: 努力实现精准医学的飞跃

2024-07-161
OAAI
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer

术前放化疗联合nivolumab治疗微卫星稳定和微卫星不稳定高位局部晚期直肠癌的三年预后

2024-06-042
PRE
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
2024-06-010
OAAI
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

TP53基因的突变谱与晚期胃癌的nivolumab治疗效果相关 (TP53MUT研究)

2023-08-024
PRE